Compositions and methods for viral sensitization
US-2024360115-A1 · Oct 31, 2024 · US
US10053672B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10053672-B2 |
| Application number | US-201414905485-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 24, 2014 |
| Priority date | Jul 25, 2013 |
| Publication date | Aug 21, 2018 |
| Grant date | Aug 21, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a method for obtaining an untransformed avian cell line enabling in vitro avian virus replication. Said method includes the following steps: a) culturing avian embryonic stem cells in the presence of a stroma for at least 3 days; b) culturing for at least 2 days in a medium having a low serum concentration; c) culturing for at least 2 days in a medium having a low serum concentration containing 1 to 10 mM of hexamethyleme bisacetamide (HMBA); d) culturing for at least 10 days in a medium having a low serum concentration; and e) culturing or freezing an avian cell line enabling avian virus replication. The invention also relates to the resulting cell line and to the use thereof in vaccine preparations.
Opening claim text (preview).
The invention claimed is: 1. A vaccinal preparation comprising a non-transformed avian cell line allowing replication of avian viruses in vitro; wherein the non-transformed avian cell line is made by a method comprising: a) cultivating avian embryonic stem cells in the presence of a stroma for at least 3 days; b) cultivating in a medium with a low serum concentration for at least 2 days; c) cultivating in a low serum concentration medium comprising between 1and 10 mM of hexamethylene bisacetamide (HMBA), for at least 2 days; and d) cultivating in a low serum concentration medium for at least 10 days; to thereby provide a non-transformed avian cell line allowing replication of avian viruses, wherein the non-transformed avian cell line expresses the following markers: CD44+, beta1 integrin, collagen 1 and OLFM3; and wherein the non-transformed avian cell line is infected with at least one avian virus.
Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696) · CPC title
Keratinocytes; Whole skin · CPC title
Cells of skeletal and connective tissues; Mesenchyme · CPC title
Organic components · CPC title
relating to complementing cells and packaging systems for producing virus or viral particles · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.